- Home
- MVSTW vs TGTX Comparison
MVSTW vs TGTX Comparison
Compare MVSTW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVSTW
- TGTX
- Stock Information
- Founded
- MVSTW 2006
- TGTX 1993
- Country
- MVSTW United States
- TGTX United States
- Employees
- MVSTW 1921
- TGTX N/A
- Industry
- MVSTW Industrial Machinery/Components
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MVSTW Miscellaneous
- TGTX Health Care
- Exchange
- MVSTW Nasdaq
- TGTX Nasdaq
- Market Cap
- MVSTW N/A
- TGTX 4.2B
- IPO Year
- MVSTW N/A
- TGTX 1995
- Fundamental
- Price
- MVSTW $0.14
- TGTX $31.99
- Analyst Decision
- MVSTW
- TGTX Strong Buy
- Analyst Count
- MVSTW 0
- TGTX 4
- Target Price
- MVSTW N/A
- TGTX $42.50
- AVG Volume (30 Days)
- MVSTW 126.0K
- TGTX 2.0M
- Earning Date
- MVSTW 03-14-2025
- TGTX 11-03-2025
- Dividend Yield
- MVSTW N/A
- TGTX N/A
- EPS Growth
- MVSTW N/A
- TGTX N/A
- EPS
- MVSTW N/A
- TGTX 0.36
- Revenue
- MVSTW $370,989,000.00
- TGTX $454,069,000.00
- Revenue This Year
- MVSTW N/A
- TGTX $82.58
- Revenue Next Year
- MVSTW N/A
- TGTX $44.99
- P/E Ratio
- MVSTW N/A
- TGTX $88.20
- Revenue Growth
- MVSTW 39.03
- TGTX 30.96
- 52 Week Low
- MVSTW $0.35
- TGTX $21.16
- 52 Week High
- MVSTW $0.44
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- MVSTW N/A
- TGTX 56.18
- Support Level
- MVSTW N/A
- TGTX $31.34
- Resistance Level
- MVSTW N/A
- TGTX $32.56
- Average True Range (ATR)
- MVSTW 0.00
- TGTX 1.12
- MACD
- MVSTW 0.00
- TGTX 0.38
- Stochastic Oscillator
- MVSTW 0.00
- TGTX 72.94
About MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.